deltatrials
Unknown PHASE3 INTERVENTIONAL 2-arm NCT02667743

Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC

Sponsor: Shanghai Yizhong Pharmaceutical Co., Ltd.

Conditions Non-Small Cell Lung Cancer(NSCLC)
Interventions Cisplatin Paclitaxel Injection Paclitaxel Micelles for Injection
Updated 12 times since 2017 Last updated: Mar 16, 2021 Started: May 31, 2015 Primary completion: Jan 31, 2019 Completion: Dec 31, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02667743, this PHASE3 trial focuses on Non-Small Cell Lung Cancer(NSCLC) and remains ongoing. Sponsored by Shanghai Yizhong Pharmaceutical Co., Ltd., it has been updated 12 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~May 2017 · 4 months · monthly snapshotRecruiting~May 2017 – ~May 2018 · 12 months · monthly snapshotRecruiting~May 2018 – ~Jun 2018 · 31 days · monthly snapshotActive Not Recruiting~Jun 2018 – ~May 2019 · 11 months · monthly snapshotActive Not Recruiting~May 2019 – ~Apr 2020 · 11 months · monthly snapshotActive Not Recruiting~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshotActive Not Recruiting~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshotActive Not Recruiting~Apr 2021 – ~Apr 2022 · 12 months · monthly snapshotActive Not Recruiting~Apr 2022 – ~Dec 2023 · 20 months · monthly snapshotUnknown Status~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  3. Dec 2023 — Jul 2024 [monthly]

    Unknown Status PHASE3

  4. Apr 2022 — Dec 2023 [monthly]

    Unknown Status PHASE3

    Status: Active Not Recruiting → Unknown Status

  5. Apr 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

▶ Show 7 earlier versions

  1. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE3

  2. Apr 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  3. May 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE3

  5. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. May 2017 — May 2018 [monthly]

    Recruiting PHASE3

  7. Jan 2017 — May 2017 [monthly]

    Recruiting PHASE3

    First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shanghai Yizhong Pharmaceutical Co., Ltd.
Data source: Shanghai Yizhong Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations